- Home
- VIGL vs HLVX Comparison
VIGL vs HLVX Comparison
Compare VIGL & HLVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VIGL
- HLVX
- Stock Information
- Founded
- VIGL 2020
- HLVX 2020
- Country
- VIGL United States
- HLVX United States
- Employees
- VIGL N/A
- HLVX N/A
- Industry
- VIGL Biotechnology: Pharmaceutical Preparations
- HLVX Biotechnology: Pharmaceutical Preparations
- Sector
- VIGL Health Care
- HLVX Health Care
- Exchange
- VIGL Nasdaq
- HLVX Nasdaq
- Market Cap
- VIGL 89.3M
- HLVX 92.6M
- IPO Year
- VIGL 2022
- HLVX 2022
- Fundamental
- Price
- VIGL $3.03
- HLVX $1.83
- Analyst Decision
- VIGL Strong Buy
- HLVX Hold
- Analyst Count
- VIGL 5
- HLVX 5
- Target Price
- VIGL $21.00
- HLVX $2.33
- AVG Volume (30 Days)
- VIGL 642.5K
- HLVX 178.9K
- Earning Date
- VIGL 03-25-2025
- HLVX 03-19-2025
- Dividend Yield
- VIGL N/A
- HLVX N/A
- EPS Growth
- VIGL N/A
- HLVX N/A
- EPS
- VIGL N/A
- HLVX N/A
- Revenue
- VIGL N/A
- HLVX N/A
- Revenue This Year
- VIGL N/A
- HLVX N/A
- Revenue Next Year
- VIGL N/A
- HLVX N/A
- P/E Ratio
- VIGL N/A
- HLVX N/A
- Revenue Growth
- VIGL N/A
- HLVX N/A
- 52 Week Low
- VIGL $1.49
- HLVX $1.55
- 52 Week High
- VIGL $6.06
- HLVX $20.22
- Technical
- Relative Strength Index (RSI)
- VIGL 77.87
- HLVX 43.02
- Support Level
- VIGL $2.71
- HLVX $1.67
- Resistance Level
- VIGL $2.95
- HLVX $1.99
- Average True Range (ATR)
- VIGL 0.21
- HLVX 0.08
- MACD
- VIGL 0.03
- HLVX -0.00
- Stochastic Oscillator
- VIGL 86.18
- HLVX 48.48
About VIGL Vigil Neuroscience Inc.
Vigil Neuroscience Inc is a microglia-focused therapeutics company treating both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel cells of the brain's immune system. It is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities to rapidly deliver precision-based therapies to improve the lives of patients and families. Its clinical candidate, iluzanebart, is currently being studied in IGNITE, a Phase 2 PoC trial and the first-ever interventional trial in ALSP patients. The company is also developing VG-3927, an orally available small molecule TREM2 agonist for the treatment of common neurodegenerative diseases associated with microglial dysfunction.
About HLVX HilleVax Inc.
HilleVax Inc is a clinical-stage biopharmaceutical company. The company is focused on developing and commercializing novel vaccines. The firm's initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.